On Friday, Shares of Yum! Brands, Inc. (NYSE:YUM), gained 1.52% to $72.77.
Business Wire declares the newest episode of Biz Wire TV, a weekly series covering trending news stories published over the newswire’s distribution network. The show spotlights stories on disruptive startups and technologies, entrepreneurs and funding declaration, hot business trends and companies to watch.
This week’s episode features:
- Flexjet to purchase 20 Aerion supersonic business jets. Tweet this!
- Ford (NYSE:F) first automaker to test autonomous vehicle at Mcity. Tweet this!
- Taco Bell (YUM) to serve cage-free eggs in 100% of U.S. restaurants. Tweet this!
- Credit Karma gives away its one billionth free credit score. Tweet this!
- The Ovarian Cancer Institute and George Tech develop procedure to detect early-stage ovarian cancer. Tweet this!
- Xenex Germ-Zapping Robot destroys Ebola virus and Anthrax spores in new study. Tweet this!
- Star Wars: The Force Awakens is teaming up with Bloomingdales and Disney Consumer Products (DIS) to launch new charity initiative. Tweet this!
- Electronic Arts (EA) launches Star Wars Battlefront. Tweet this!
- Ronda Rousey featured on the cover of EA Sports UFC 2. Tweet this!
- Barnes & Noble (BKS) declares holiday ad campaign featuring Tony Bennett and Lady Gaga. Tweet this!
- Carvana opens world’s first, fully-automated, coin-operated car vending machine. Tweet this!
A core component of the video programming is news-related data analysis powered by Business Wire’s NewsTrak reports and NUVI social media tracking. BizWireTV is hosted by Erin Ade. Watch for new episodes each Friday available on www.BusinessWire.com
YUM! Brands, Inc., together with its auxiliaries, operates quick service restaurants. It operates in five segments: YUM China, YUM India, the KFC Division, the Pizza Hut Division, and the Taco Bell Division.
Shares of Anthem Inc (NYSE:ANTM), inclined 2.60% to $131.19, during its last trading session.
“For more than 75 years, Anthem has assisted individuals to access and finance quality healthcare,” said Joseph R. Swedish, President and Chief Executive Officer, Anthem. “As a leader during this time of unprecedented transformation in healthcare, Anthem remains committed to enhancing access to high quality, affordable healthcare for all of our members inside and outside of the insurance exchanges and ongoing our dialogue with policymakers and regulators regarding how we can improve the stability of the individual market. Since the launch of the insurance exchanges, Anthem has offered more than 1,000 new insurance product choices in 14 states across the country — more than any other healthcare insurer. Recently, we serve more than 1.7 million individuals with our trusted and caring solutions.
Anthem, Inc., through its auxiliaries, operates as a health benefits company in the United States. It operates through three segments: Commercial and Specialty Business, Government Business, and Other.
Finally, Shares of Vital Therapies Inc (NASDAQ:VTL), ended its last trade with 10.18% gain, and closed at $8.66.
Vital Therapies, Inc. (VTL), a biotherapeutic company developing ELAD(R), a cell-based therapy targeting the treatment of liver failure, declared that it has received written responses from the FDA to its Type C meeting request on the planned VTL-308 phase 3 clinical trial.
At the FDA’s suggestion, the Company has incorporated an event-driven feature into the trial design consistent with the primary endpoint of overall survival. Under the modified design, enrollment will continue until at least 150 subjects have been enrolled and 55 events have occurred, consistent with the event rate seen in the target subpopulation from VTI-208.
In light of the FDA’s guidance on trial design and other topics, the VTL-308 program remains on track. Clinical sites are in the process of opening, with enrollment of the first subject predictable in the first half of 2016, and final data anticipated in mid-2018.
Vital Therapies, Inc., a biotherapeutic company, focuses on developing a cell-based therapy for the treatment of acute liver failure in the United States. Its ELAD system is an extracorporeal bio-artificial liver therapy that is in Phase III clinical trials to allow the patient’s own liver to regenerate to a healthy state, or to stabilize the patient until transplant.